Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial

OBJECTIVES: To determine whether hydroxychloroquine decreases the risk of adverse outcome in patients with mild to moderate coronavirus disease 2019 (COVID-19) at high risk of worsening. METHODS: We conducted a multicentre randomized double-blind placebo-controlled trial evaluating hydroxychloroquin...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubée, Vincent, Roy, Pierre-Marie, Vielle, Bruno, Parot-Schinkel, Elsa, Blanchet, Odile, Darsonval, Astrid, Lefeuvre, Caroline, Abbara, Chadi, Boucher, Sophie, Devaud, Edouard, Robineau, Olivier, Rispal, Patrick, Guimard, Thomas, d’Anglejean, Emma, Diamantis, Sylvain, Custaud, Marc-Antoine, Pellier, Isabelle, Mercat, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015393/
https://www.ncbi.nlm.nih.gov/pubmed/33813110
http://dx.doi.org/10.1016/j.cmi.2021.03.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015393/
https://www.ncbi.nlm.nih.gov/pubmed/33813110
http://dx.doi.org/10.1016/j.cmi.2021.03.005

Ejemplares similares